Literature DB >> 11535707

Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study.

J Berumen1, R M Ordoñez, E Lazcano, J Salmeron, S C Galvan, R A Estrada, E Yunes, A Garcia-Carranca, G Gonzalez-Lira, A Madrigal-de la Campa.   

Abstract

BACKGROUND: Human papillomavirus 16 (HPV16) has a number of variants, each with a different geographic distribution and some that are associated more often with invasive neoplasias. We investigated whether the high incidence of cervical cancer in Mexico (50 cases per 100 000 women) may be associated with a high prevalence of oncogenic HPV16 variants.
METHODS: Cervical samples were collected from 181 case patients with cervical cancer and from 181 age-matched control subjects, all from Mexico City. HPV16 was detected with an E6/E7 gene-specific polymerase chain reaction, and variant HPV classes and subclasses were identified by sequencing regions of the E6 and L1/MY genes. Clinical data and data on tumor characteristics were also collected. All statistical tests were two-sided.
RESULTS: HPV16 was detected in cervical scrapes from 50.8% (92 of 181) of case patients and from 11% (20 of 181) of control subjects. All HPV16-positive samples, except one, contained European (E) or Asian-American (AA) variants. AA and E variants were found statistically significantly more often in case patients (AA = 23.2% [42 of 181]; E = 27.1% [49 of 181]) than in control subjects (AA = 1.1% [two of 181]; E = 10% [18 of 181]) (P<.001 for case versus control subjects for either E or AA variants, chi2 test). However, the frequency of AA variants was 21 times higher in cancer patients than in control subjects, whereas that ratio for E variants was only 2.7 (P =.006, chi2 test). The odds ratio (OR) for cervical cancer associated with AA variants (OR = 27.0; 95% confidence interval [CI] = 6.4 to 113.7) was higher than that associated with E variants (OR = 3.4; 95% CI = 1.9 to 6.0). AA-positive case patients (46.2 +/- 12.5 years [mean +/- standard deviation]) were 7.7 years younger than E-positive case patients (53.9 +/- 12.2 years) (P =.004, Student's t test). AA variants were associated with squamous cell carcinomas and adenocarcinomas, but E variants were associated with only squamous cell carcinomas (P =.014, Fisher's exact test).
CONCLUSIONS: The high frequency of HPV16 AA variants, which appear to be more oncogenic than E variants, might contribute to the high incidence of cervical cancer in Mexico.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535707     DOI: 10.1093/jnci/93.17.1325

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  84 in total

Review 1.  Human papillomavirus genome variants.

Authors:  Robert D Burk; Ariana Harari; Zigui Chen
Journal:  Virology       Date:  2013-08-31       Impact factor: 3.616

2.  New HPV-16 European and non-European variants in Central Brazil.

Authors:  Tainá Raiol Alencar; Daniela Marreco Cerqueira; Márcio Rojas da Cruz; Patrícia Soares Wyant; Eduardo Dias Ramalho; Cláudia Renata Fernandes Martins
Journal:  Virus Genes       Date:  2006-10-18       Impact factor: 2.332

3.  Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.

Authors:  Rosemary E Zuna; William E Moore; Rebecca P Shanesmith; S Terence Dunn; Sophia S Wang; Mark Schiffman; Gregory L Blakey; Travis Teel
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

4.  Cancer of the cervix - from bleak past to bright future; a review, with an emphasis on cancer of the cervix in malaysia.

Authors:  Othman Nor Hayati
Journal:  Malays J Med Sci       Date:  2003-01

5.  Human papillomavirus 45 genetic variation and cervical cancer risk worldwide.

Authors:  Alyce A Chen; Daniëlle A M Heideman; Debby Boon; Tarik Gheit; Peter J F Snijders; Massimo Tommasino; Silvia Franceschi; Gary M Clifford
Journal:  J Virol       Date:  2014-02-05       Impact factor: 5.103

6.  The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenografts.

Authors:  Maria Filippova; Whitney Evans; Robert Aragon; Valery Filippov; Vonetta M Williams; Linda Hong; Mark E Reeves; Penelope Duerksen-Hughes
Journal:  Virology       Date:  2014-01-01       Impact factor: 3.616

7.  Prevalence of human papillomavirus in university young women.

Authors:  Maria T Montalvo; Ismelda Lobato; Hilda Villanueva; Celia Borquez; Daniela Navarrete; Juan Abarca; Gloria M Calaf
Journal:  Oncol Lett       Date:  2011-04-06       Impact factor: 2.967

8.  Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.

Authors:  Ingeborg Zehbe; Christina Richard; Correne A DeCarlo; Anny Shai; Paul F Lambert; Hava Lichtig; Massimo Tommasino; Levana Sherman
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

9.  Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus.

Authors:  Jianduan Li; Daniela S Gerhard; Zhengyan Zhang; Phyllis C Huettner; Jason Wright; Loan Nguyen; Danielle Lu; Janet S Rader
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

10.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.